ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

NSABP Accrual Slow, But Auditing Called “Impressive”

January 20, 1995

NCI Role, Issues In Education Considered By DRCCA Board

August 21, 1981

In Brief: Schmidt Confers With Califano, Fredrickson On NCI director; Senate Hearing March 15-16

February 18, 1977

Cancer Program Advocates, Success Overcame Powerful Negative Factors To Win Budget Fight

August 10, 1979

Clinical Trial System Inefficient, UPCI Director Tells Senate

June 7, 2002

Conferees Agree On $815 Million For NCI In ‘77

July 30, 1976